GC Corp. 3
3 · Artiva Biotherapeutics, Inc. · Filed Jul 18, 2024
Insider Transaction Report
Form 3
GC Corp.
10% Owner
Holdings
Series A Preferred Stock
→ Common Stock (667,185 underlying)- 232,558(indirect: By GC Cell Corporation)
Common Stock
Series B Preferred Stock
→ Common Stock (330,095 underlying)- (indirect: By GC Cell Corporation)
Series A Preferred Stock
→ Common Stock (292,791 underlying) - (indirect: By GC Cell Corporation)
Series B Preferred Stock
→ Common Stock (62,181 underlying) - 348,837
Common Stock
Footnotes (3)
- [F1]GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by CG Corp., except to the extent of any pecuniary interest therein.
- [F2]The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein.
- [F3]Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") is convertible into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering, the Preferred Stock will convert into the number of shares of Common Stock of the Issuer shown in column 3. The Preferred Stock has no expiration date.